+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 99Years
All Genders
ID05223413

Remote Ischemic PreConditioning to Prevent Heart Damage in Lymphoma Patients Receiving Anthracycline Chemotherapy

Led by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III · Updated on 2026-10-29

608

Participants Needed

24

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a multinational, prospective, proof of concept phase II randomized clinical trial to assess the safety and effectiveness of Remote Ischemic PreConditioning RIPC in patients with lymphoma who are receiving anthracycline chemotherapy. This study uses a double-blinded, sham-controlled design to compare RIPC with a simulated procedure in patients undergoing at least five chemotherapy cycles. Participants will be randomly assigned to receive either weekly RIPC or a sham procedure during their chemotherapy treatment. Each session involves four cycles of 5 minutes of blood pressure cuff inflation followed by 5 minutes of deflation on the arm, with RIPC inflating to 200 mmHg to stop blood flow and sham inflating to a low pressure that does not stop blood flow. Baseline cardiac magnetic resonance imaging CMR and blood tests will be performed before chemotherapy, with follow-up CMR and blood tests after the third and last chemotherapy cycles, and again nine weeks after finishing chemotherapy. Patients will be monitored for clinical events up to 42 months after treatment. Throughout the study, participants will undergo multiple assessments including CMR scans, blood tests measuring cardiac markers, and questionnaires evaluating quality of life related to hematological malignancy and cardiomyopathy. Researchers will track the rate of cardiotoxicity induced by anthracyclines, changes in heart function, tumor regression, hospitalizations for heart failure, and quality of life changes. The total follow-up period for clinical outcomes is expected to be about 36 months on average, with the study concluding when the last patient completes their final evaluations.

CONDITIONS

Brief Title

REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs

Research Team

B

Borja Ibañez, MD PhD FESC

N

Noemi Escalera

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here